GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lisata Therapeutics Inc (LTS:0HS8) » Definitions » Institutional Ownership

Lisata Therapeutics (LTS:0HS8) Institutional Ownership : 4.06% (As of Dec. 14, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Lisata Therapeutics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Lisata Therapeutics's institutional ownership is 4.06%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Lisata Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Lisata Therapeutics's Float Percentage Of Total Shares Outstanding is 81.25%.


Lisata Therapeutics Institutional Ownership Historical Data

The historical data trend for Lisata Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lisata Therapeutics Institutional Ownership Chart

Lisata Therapeutics Historical Data

The historical data trend for Lisata Therapeutics can be seen below:

2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31 2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31
Institutional Ownership 3.75 3.68 3.75 3.82 3.85 3.93 3.93 3.98 4.04 4.06

Lisata Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Lisata Therapeutics Business Description

Traded in Other Exchanges
Address
110 Allen Road, 2nd Floor, Basking Ridge, NJ, USA, 07920
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.

Lisata Therapeutics Headlines

No Headlines